SecBot SecBot
Insider Cluster (3 insiders) ·Filed Sep 1, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed2mo ago
Insider cluster: 3 insiders, $0.3M total
Actionable Insight • Neutral

Monitor for additional Form 4 filings in the next 30 days, if selling accelerates above 0.1% of market cap or includes the CEO/CFO, the signal strengthens. For now, the small dollar amount relative to XERS's $1.5B market cap makes this a neutral data point; the stock's recent strength and strong analyst coverage suggest no bearish read-through.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$8.58
T+0 close · Sep 1, 2026 · via day close
Latest settled
+11.42%
T+20 · $9.56 · next T+60 in 10d
Vs SPY
+11.51%
α at T+20
Latest observation
+110.39%
T+52 · FF3 residual α
  1. T+0 · Sep 2 $8.58entry
  2. T+1 · 3mo ago +0.12%α −0.93% · $8.59
  3. T+5 · 2mo ago −10.61%α −9.65% · $7.67
  4. T+20 · 7w ago +11.42%α +11.51% · $9.56
  5. T+52 · todayOpen
  6. T+60 · in 10d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three Xeris Biopharma insiders (McCulloch, Hecht, Pieper) sold a combined $311K in open-market shares on September 1, 2026 at ~$8.49-$8.50 per share. While a cluster of C-suite selling is notable, the total value represents ~0.02% of the $1.5B market cap, well below the 0.1% materiality threshold, and the sales coincide with the stock near multi-year highs, suggesting routine portfolio diversification rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$311.2K
Insiders
3

Key Facts

  • Three executives, McCulloch, Hecht, Pieper, sold a total of $311,242 in open-market sales on September 1, 2026
  • Sales executed at $8.49-$8.50 per share, near XERS's recent highs
  • Total sales equal ~0.02% of the $1.5B market cap, well below the 0.1% materiality threshold
  • All three sellers have 'See Remarks' titles, likely C-suite or senior operational roles

Financial Impact

Open-market sales of $311K represent ~0.02% of market cap

insider ownership

Risk Factors

  • Sales could accelerate if insiders diversify further ahead of potential Q3 2026 earnings
  • Stock at multi-year highs may invite profit-taking by other holders

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-XERS-1788301306922

US Market Status

Market Closed · Opens in 5h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026